# Telehealth PT-141 — The Bremelanotide Telemedicine Pathway, Documented > Procedural overview of how qualified clinicians evaluate and prescribe bremelanotide (PT-141) by synchronous video visit, under federal and state telemedicine law. Editorial reference, not a clinic. An information manual on how qualified clinicians evaluate and prescribe bremelanotide through synchronous video consultation, under federal and state telemedicine law. ## DOC.00 // PLAIN BRIEF Bremelanotide (research designation: PT-141) is a synthetic peptide that activates melanocortin receptors in the brain — not blood vessels — and is the only FDA-approved drug for acquired, generalized low sexual desire (HSDD) in premenopausal women. Approved June 2019 (NDA 210557), it is given as a single 1.75 mg injection under the skin, taken as needed before anticipated sexual activity. Because it is not a controlled substance, most U.S. states allow it to be evaluated and prescribed by synchronous video visit without a prior in-person examination. The Ryan Haight Act's in-person rule applies only to scheduled drugs; bremelanotide is not scheduled. This site is an editorial manual on how that telehealth pathway works in practice — what the federal baseline says, what state medical boards require, what the trial record shows, and what the safety screening must cover. See the [effects and safety page](/effects) for the reported benefits and cited cautions. ## What this site is Telehealth PT-141 is an editorial reference. It is not a clinic, not a telehealth platform, and not a pharmacy. It does not provide medical care, schedule appointments, or sell or dispense any product. The pages collected here describe how the bremelanotide telemedicine pathway works on paper — what the federal Controlled Substances Act says, what state medical boards require, what the FDA-approved label specifies, and how the published sexual-medicine literature describes the remote evaluation of hypoactive sexual desire disorder (HSDD). Bremelanotide — known in the development literature as PT-141 — is a synthetic cyclic heptapeptide melanocortin receptor agonist [01]. The U.S. Food and Drug Administration approved it on June 21, 2019 for the treatment of acquired, generalized HSDD in premenopausal women, at a single recommended dose of 1.75 mg by subcutaneous injection, taken as needed approximately 45 minutes before anticipated sexual activity [06][10]. That single regulatory fact — a non-controlled prescription drug, with one approved indication, dosed as needed — is what shapes the entire telehealth pathway. ## Why telehealth applies here Two regulatory facts decide whether a medication can be prescribed remotely without an in-person visit. First: is the drug a controlled substance under the federal Controlled Substances Act? Bremelanotide is not [12][19]. Second: do state medical-board rules in the patient's state permit the establishment of a provider-patient relationship by synchronous audiovisual encounter for non-controlled prescribing? In most states, the answer is yes [12][18]. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008, the federal statute most often cited in online-prescribing debates, requires at least one in-person evaluation before a controlled substance can be prescribed over the internet. It applies only to Schedule II–V drugs. Because bremelanotide is not scheduled, the Ryan Haight in-person requirement does not apply to it [12][19]. State medical boards govern the rest — informed consent, documentation, follow-up, and the standard of care. This distinction is the spine of the entire telehealth bremelanotide workflow. The pages here document it in order. ## What the evidence supports The FDA approval rests on two adequate and well-controlled Phase 3 trials, RECONNECT 301 and RECONNECT 302, which together randomized 1,267 premenopausal women with acquired, generalized HSDD to bremelanotide 1.75 mg subcutaneous as-needed versus placebo. Both co-primary endpoints — change from baseline on the Female Sexual Function Index desire domain (FSFI-D) and on Item 13 of the Female Sexual Distress Scale (FSDS-DAO Item 13) — reached statistical significance, with FSFI-D treatment differences of 0.30 (Study 301, p<0.001) and 0.42 (Study 302, p<0.001) [01]. A 52-week open-label extension sustained those effects without new safety signals [02]. Integrated subgroup analyses across the development program confirmed that the treatment effect held across age, body-mass index, baseline testosterone, hormonal contraceptive use, and HSDD duration [04]. The sexual-medicine telehealth literature complements this picture. A 2020 review concluded that the majority of sexual-medicine encounters — including history-taking, validated-questionnaire administration, counseling, and non-controlled prescribing — can be conducted by video visit when documentation, consent, and state licensure standards are met [15]. A 2021 retrospective at a major academic sexual-medicine center documented stable racial and ethnic diversity in remote encounters during the COVID-19 expansion, with persistent access gaps for patients over 60, non-English speakers, and patients without broadband [16]. The 2025 ACOG Committee Statement No. 20 endorses telehealth as ethically appropriate for many ambulatory women's-health services when the standard of care is preserved [18]. The 5th International Consultation on Sexual Medicine, published in 2025, lists bremelanotide as an as-needed pharmacotherapy option for premenopausal HSDD with moderate evidence support [12]. ## What the safety profile requires Bremelanotide's tolerability profile is not subtle. Across the integrated clinical program of roughly 3,500 subjects, the most common adverse events at the 1.75 mg dose were nausea (40.0%), flushing (20.3%), headache (11.3%), and injection-site reactions (13.2%) [03]. Nausea was the dominant reason for discontinuation, at roughly 8% of subjects [03]. An ambulatory blood pressure monitoring study in 397 premenopausal women showed small, transient post-dose systolic blood pressure increases of 2.4–3.2 mmHg, peaking within four hours and resolving within twelve [05]. The label contraindicates bremelanotide in uncontrolled hypertension or known cardiovascular disease [06][12]. Co-administration with oral naltrexone reduced naltrexone exposure substantially and is excluded by the label [07]. Focal hyperpigmentation of the face, gums, or breasts was reported in approximately 1% of trial participants and may not fully resolve after discontinuation [08]. None of these signals are exotic. All of them are screenable in a video visit when the encounter is structured to capture medication history, blood-pressure history (self-reported or measured at home), skin-type history, and informed consent. The procedural pages here describe how a clinician sets up that screen. ## How to read this manual The pages are ordered by document number. DOC.01 is the research summary — mechanism, the RECONNECT trial results, and the telehealth-specific literature. DOC.02 is the dosage page — what the FDA label specifies, the pharmacokinetic profile that makes on-demand patient-self-administered dosing viable, and the dose-finding trial that selected 1.75 mg. DOC.03 is the frequently-asked-questions page. DOC.04 is the procedural workflow — intake, video visit, evaluation, consent, prescription, fulfillment, follow-up. DOC.05 is the references list. DOC.06 explains who publishes this site and on what authority. DOC.07 is contact. Every quantitative claim on every page cites a published source. The semantic color coding is consistent: a red mark signals contraindication or alert, an ochre mark signals caution or caveat, a navy mark signals an informational or regulatory note, a green mark signals a compliant or permitted status. The legend is repeated on data-dense pages. --- An independent editorial digest of peer-reviewed literature and regulatory documents on the bremelanotide telehealth pathway — not a clinic, not a pharmacy, not medical advice.